DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising ...

The warning letter follows inspections by the FDA at Dexcom’s manufacturing facilities in San Diego and Mesa, Ariz., and ...

The company does not expect the warning letter to materially impact its manufacturing capacity, sales or ability to seek ...

not a long-term thing that we will have to do because we see that if they have that CGM on, it’s more reliable,” said Dr. Bruner-Hill In a post on Dexcom’s website, the company said if you are unable ...

Dexcom has received a warning letter from the FDA, after the agency uncovered issues during two inspections of the continuous ...

Any time we try a healthy new way of eating, it’s easy for doubt to creep in. Is it really working? Is it worth it? Does it ...

Trinity Biotech (Nasdaq:TRIB) today announced the next stage of its transformation plan as it looks to bring a CGM to market.

DexCom said that on Tuesday it received a warning letter from the U.S. FDA following inspections at its facilities in San Diego, Calif., and Mesa, Ariz. related to concerns about manufacturing ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss how continuous glucose monitoring (CGM) adoption impacts clinical inertia and ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

This program was supported through an independent medical education grant from Dexcom Medical Affairs. Experts discuss the key benefits of continuous glucose monitoring (CGM) technology compared with ...